Story perspectives

Private Capital Revives Parkinson's Trials Amid FDA Challenges

3/20/2026

48 8

Summary

Story summary

In Q1 2026, private capital re-enters late-stage CNS trials, creating a CNS Registrational Gap for advanced Parkinson's disease.
Serina Therapeutics announced $30 million in funding for SER-252 with shares priced at a 68% premium.
The FDA's evolving endpoint standards complicate trial designs and require patient-reported outcomes.
Current operational models remain misaligned with FDA guidance, risking enrollment delays.
The industry must adapt to meet regulatory expectations and patient needs.

History

Historical Context

The 21st Century Cures Act, enacted by the FDA in 2016, aimed to expedite drug development and enhance clinical trials, reflecting ongoing challenges in the pharmaceutical industry. This legislation facilitated significant funding, exemplified by Serina Therapeutics raising $30 million for innovative treatments. Historical struggles with regulatory frameworks, particularly in the 1990s, underscore the importance of aligning operational models to improve therapies for conditions like Parkinson's disease.

1 of 2

Story summary

In Q1 2026, private capital re-enters late-stage CNS trials, creating a CNS Registrational Gap for advanced Parkinson's disease.
Serina Therapeutics announced $30 million in funding for SER-252 with shares priced at a 68% premium.
The FDA's evolving endpoint standards complicate trial designs and require patient-reported outcomes.
Current operational models remain misaligned with FDA guidance, risking enrollment delays.
The industry must adapt to meet regulatory expectations and patient needs.

1 / 2